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Background {#sec001}
==========

Different from the third and fourth generations of cephalosporins, carbapenems are currently more consistently active against *Enterobacteriaceae* because carbapenems are not inactivated by extended-spectrum β-lactamases (ESBLs) or plasmid-encoded AmpC cephalosporinases. Resistance to carbapenems is relatively rare; therefore, this class of drugs is considered the last option for the treatment of severe infections.

Carbapenemases are described as chromosomally-encoded β-lactamases prior to the identification of plasmid-encoded IMP-1, OXA-23 (ARI-1), and KPC-2. The emergence of plasmids containing carbapenemase genes, including KPC-type (class A), as well as IMP-,VIM-, and NDM-types (class B), is considered a serious threat as the emergence of plasmids containing carbapenemase genes facilitates the dissemination of carbapenem resistance \[[@pone.0139152.ref001]\], and the carbapenemases hydrolyze almost all β-lactams. Indeed, plasmid-borne carbapenemases have been isolated worldwide, including Taiwan \[[@pone.0139152.ref001]--[@pone.0139152.ref004]\]. After the first identification of a *Klebsiella pneumoniae* strain expressing plasmid-encoded class D carbapenemase OXA-48 in Istanbul \[[@pone.0139152.ref005]\], the incidence of OXA-48 expression by *Enterobacteriaceae* has increased dramatically in Mediterranean countries \[[@pone.0139152.ref006]\]. In 2012, a 4-year surveillance program was initiated in Taiwan to investigate carbapenem resistance mechanisms, especially with respect to plasmid-borne carbapenemases in *K*. *pneumoniae* and *Escherichia coli*. Herein we report the identification of the first four isolates expressing OXA-48 during this surveillance program.

Methods {#sec002}
=======

Bacterial strains and susceptibility testing {#sec003}
--------------------------------------------

The participating hospitals in the national survey identified imipenem or meropenem non-susceptible *K*. *pneumoniae* and *E*. *coli* isolates and sent the isolates to a reference laboratory at the National Health Research Institutes of Taiwan. A total of 760 imipenem- or meropenem-non-susceptible *K*. *pneumoniae* and 144 imipenem- or meropenem-non-susceptible *E*. *coli* isolates were consecutively collected from 18 hospitals (11 medical centers and 7 regional hospitals) between January 2012 and April 2014. The participating hospitals in the surveillance program distributed in all regions of the country. The regional hospitals can handle most diseases and injuries; however, medical centers provide services with more specialists, especially critical care specialist and specialists who can diagnose and treat immune-compromised patients. All the isolates were from individual cases.

This study was approved by the Institutional Review Boards of all participating hospitals, including Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH-IRB-20110328), Linkou Chang Gung Memorial Hospital (1003399B), Chung Shan Medical University Hospital (CSMUH-CS-12187), and National Taiwan University Hospital (201110043RB).

The isolates were obtained as part of routine hospital care procedures, and written informed consent for participation in the study was waived. The primary screening for carbapenem resistance was performed by the individual participating hospitals. Further confirmation of antimicrobial susceptibility was determined using the broth micro-dilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) \[[@pone.0139152.ref007]\].

Minimum inhibitory concentrations (MICs) for carbapenems (ertapenem, imipenem, meropenem, and doripenem) and other antimicrobial agents, including cefazolin, cefotaxime, cefoxitin, cefepime, ciprofloxacin, amikacin, gentamicin, trimethoprim-sulfamethoxazole (SXT), colistin, and tigecycline, were determined using the broth micro-dilution method (Sensititre; Trek Diagnostic Systems, Cleveland, OH, USA). CLSI M100-S24 \[[@pone.0139152.ref008]\] interpretive breakpoints were used to interpret the MIC results for all antimicrobial agents studied, with the exception of tigecycline and colistin. The Food and Drug Administration (FDA) breakpoint was used for tigecycline and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint was used for colistin.

Detection of genes encoding carbapenemases, AmpC, and ESBLs {#sec004}
-----------------------------------------------------------

Carbapenemase genes (e.g., class B families \[*bla* ~IMP~, *bla* ~VIM~, *bla* ~NDM~, *bla* ~GIM~, *bla* ~SPM~, and *bla* ~SIM~\], class A families \[*bla* ~NMC~, *bla* ~IMI~, *bla* ~SME~, *bla* ~KPC~, and *bla* ~GES~\], and class D \[*bla* ~OXA-48~\]), plasmid-encoding AmpC (e.g., *bla* ~CMY~, *bla* ~DHA~, *bla* ~FOX~, and *bla* ~ACT~) \[[@pone.0139152.ref009]\], and ESBL genes (e.g., *bla* ~CTX-M~, *bla* ~TEM~, and *bla* ~SHV~) were detected by PCR amplification \[[@pone.0139152.ref004]\]. The amplicons were sequenced, and the entire sequence of each gene was compared to the sequences in the GenBank nucleotide database at <http://www.ncbi.nlm.nih.gov/blast/>.

Characteristics of *bla* ~OXA-48~-containing plasmids {#sec005}
-----------------------------------------------------

Plasmid conjugation was performed using *E*. *coli* J53 AzR as the recipient strain. The recipients and *bla* ~OXA-48~--carrying donor samples were separately inoculated into brain-heart infusion broth and incubated at 37°C for 4 h. The samples were then mixed at a ratio of 10:1 (donor: recipient \[*v*: *v*\]) for an overnight incubation at 37°C. A 0.1-mL aliquot of the overnight broth mixture was spread onto a MacConkey agar plate containing sodium azide (100 μg/mL) and imipenem (1 μg/mL). The plasmids were extracted from these conjugants using a standard alkaline lysis method, and the fingerprints of the plasmids were generated by digestion with *Eco*RI (New England Biolabs, Beverly, MA, USA), as previously described \[[@pone.0139152.ref010]\]. Plasmid incompatibility was determined by a PCR-based replicon typing scheme, as previously described \[[@pone.0139152.ref011]\]. PCR and sequencing of the upstream of *bla* ~OXA-48~ gene were performed using the following primers in this study: OXA-48F, 5'-CGCATCTTGTTGTCCAAGTG-3'; and OXA-48R, 5'-TCGAGCATCAGCATTTTGTC-3'. The full sequence length was 1012 bp.

Pulsed-field gel electrophoresis (PFGE) {#sec006}
---------------------------------------

Total DNA was prepared and digested with *Xba*I (New England Biolabs), as suggested by the manufacturer. The restriction fragments were separated by PFGE in a 1% agarose gel (Bio-Rad, Hercules, CA, USA) with 0.5× TBE buffer (45mM Tris, 45mM boric acid, and 1.0mM EDTA \[pH 8.0\]) for 22 h at 200 V and 14°C, with ramp times of 2--40 s using a CHEF Mapper apparatus (Bio-Rad Laboratories, Richmond, CA, USA). The Dice coefficient was used to calculate similarities, and the unweighted pair-group method with the arithmetic mean (UPGMA) was used for the cluster analysis using the BioNumerics software (version 5.10; Applied Maths, St-Martens-Latem, Belgium).

Multi-locus Sequence Type {#sec007}
-------------------------

Multi-locus sequence typing (MLST) was performed on the four OXA-48-positive *K*. *pneumoniae* isolates according to the protocol described on the *K*. *pneumoniae* MLST website (<http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumonia.html>). MLST results were typed according to the international *K*. *pneumoniae* MLST database, which was created in 2005 at the Pasteur Institute in Paris, France.

Results {#sec008}
=======

An overall description of the findings in the surveillance program {#sec009}
------------------------------------------------------------------

Of 760 carbapenem non-susceptible *K*. *pneumoniae* (CnSKP) isolates, the resistant rates to imipenem, meropenem, doripenem, and ertapenem were 74.7%, 68.3%, 67.3%, and 92.3%, respectively. Carbapenemases were detected in 210 CnSKP isolate (27.6%), including 162 KPC-2, 4 OXA-48, 18 IMP-8, 24 VIM-1, and 1 each of KPC-3, KPC-17, and NDM-1. Almost all KPC-2 CnSKP isolates had the same PFGE type and belonged to MLST ST11. The four *bla* ~OXA-48~ CnSKP isolates were detected in late 2013.

Case descriptions {#sec010}
-----------------

None of the patients had a travel history abroad. Isolates 1 and 2 were acquired in one hospital in central Taiwan. The isolates possessed the same genes, including *bla* ~OXA-48~, *bla* ~CTX-M-14~, *bla* ~TEM-31~, and *bla* ~SHV-11~. Patient 1 was an 85-year-old female who suffered from pneumonia with poorly controlled type 2 diabetes. She was admitted to another hospital before being transferred. The use of antibiotics was not known. Patient 2 was a 78-year-old female who had sepsis, hospital-acquired pneumonia, and a catheter-related infection. The patient was treated with ertapenem for 7 days prior to isolation of the resistant strain. Patients 1 and 2 had overlapping stays in the same unit, which suggested an epidemiologic relationship between cases 1 and 2. Isolates 3 and 4 were isolated from two different medical centers within the same city in northern Taiwan; however, there were no patient transfers between these two centers for the two cases. Isolate 3, which carried *bla* ~OXA-48~, *bla* ~CTX-M-15~, *bla* ~TEM-1~, and *bla* ~SHV-11~, was obtained from an 82-year-old hospitalized patient who had pneumonia and was transferred from another hospital. Isolate 4 was obtained from a 56-year-old outpatient who had a toothache and had received treatment for dental caries in a community clinic. Isolate 4 had no other extended-spectrum cephalosporinase genes and no permeability defects; isolate 4 was susceptible to the late generation cephalosporins, but resistant to carbapenems. No epidemiologic linkage was found between cases in northern and central Taiwan.

Susceptibilities and extended spectrum β-lactamases of four OXA-48 producers {#sec011}
----------------------------------------------------------------------------

The antimicrobial susceptibility pattern and the β-lactamases genes carried by the four *K*. *pneumoniae* isolates carrying *bla* ~OXA-48~ are presented in [Table 1](#pone.0139152.t001){ref-type="table"}. Isolate 4 (from case 4) harboured *bla* ~OXA-48~ alone and was resistant to ampicillin, cefazolin, piperacillin-tazobactam, ticarcillin-clavulanate, ertapenem, imipenem, meropenem, and doripenem. Isolate 4 had intermediate resistance to cefuroxime and was susceptible to cefotaxime, ceftazidime, cefepime, aztreonam, cefoxitin, gentamicin, amikacin, nalidixic acid, ciprofloxacin, trimethoprim-sulfamethoxazole, colistin and tigecycline ([Table 1](#pone.0139152.t001){ref-type="table"}). Isolates 1 and 2 harboured *bla* ~OXA-48~, *bla* ~CTX-M-14~, and *bla* ~TEM-31~, and were resistant to all of the above antibiotics except colistin and tigecycline. Isolate 3 encoded *bla* ~OXA-48~ and *bla* ~CTX-M-15~, and was resistant to all of the above antibiotics, except tigecycline ([Table 1](#pone.0139152.t001){ref-type="table"}).

10.1371/journal.pone.0139152.t001

###### Genetic features of four *bla* ~OXA-48~ *Klebsiella pneumoniae*.

![](pone.0139152.t001){#pone.0139152.t001g}

  Isolate   Specimen   β-lactam MICs (μg/mL)   ST type   Non-β-lactamassociated resistance   Associated β-lactamases   Inc                                                         
  --------- ---------- ----------------------- --------- ----------------------------------- ------------------------- ----- ----- -------------------- -------------------------- --------
  1         sputum     ≥8                      ≥8        ≥8                                  ≥32                       ≥64   11    Gm, Ak, Q, SXT       CTX-M-14, TEM-31, SHV-11   IncA/C
  2         urine      ≥8                      ≥8        ≥8                                  16                        ≥64   11    Gm, Ak, Q, SXT       CTX-M-14, TEM-31, SHV-11   IncA/C
  3         urine      ≥8                      ≥8        ≥8                                  ≥32                       ≥64   11    Gm, Ak, Q, SXT, Cs   CTX-M-15, TEM-1, SHV-11    IncA/C
  4         urine      ≥8                      ≥8        4                                   ≤1                        ≤1    116   none                 SHV-1                      NT

ERT: ertapenem; IMP: imipenem; MER: meropenem; CAZ: ceftazidime; CTX: ceftaxime; Gm: gentamicin; Ak: amikacin; Cs: colistin; MIC: minimum inhibitory concentration; SXT: trimethoprim-sulfamethoxazole; Q: fluoroquinolones; NT: not-typeable

Plasmid digestion profile {#sec012}
-------------------------

Molecular analysis with PCR and plasmid extraction of the *E*. *coli* conjugants revealed that *bla* ~OXA-48~ and *bla* ~CTX-M~ were detected on the same plasmid in isolates 1--3. The plasmid belongs to the incompatibility group, IncA/C ([Table 1](#pone.0139152.t001){ref-type="table"}). The incompatibility group of the plasmid from isolate 4 was not typeable by the PCR-based replicon typing method. The plasmids of conjugants of isolates 1, 2, and 3 exhibited similar restriction profiles (*Eco*RI digested; [Fig 1](#pone.0139152.g001){ref-type="fig"}). The upstream (950 bp) of all 4 plasmids were identical to pKP~OXA~-48N1 (GenBank database accession number KC757416) \[[@pone.0139152.ref012]\].

![EcoRI-digested plasmid digestion profile of four OXA-48-producing *Klebsiella pneumoniae* isolates.\
M, marker.](pone.0139152.g001){#pone.0139152.g001}

PFGE and MLST analyses {#sec013}
----------------------

As shown in [Fig 2](#pone.0139152.g002){ref-type="fig"}, PFGE revealed 3 clones; isolates 1 and 2 were the same clone and distinct from isolates 3 and 4. Analysis of the ST type revealed that isolates 1--3 belong to ST11, and isolate 4 belongs to ST116 ([Table 1](#pone.0139152.t001){ref-type="table"} and [Fig 2](#pone.0139152.g002){ref-type="fig"}).

![Dendrogram of XbaI-digested genomic DNA of four OXA-48 producing *Klebsiella pneumoniae* isolates.](pone.0139152.g002){#pone.0139152.g002}

Discussion {#sec014}
==========

Because *bla* ~OXA-48~ was first detected in *K*. *pneumoniae* in Turkey \[[@pone.0139152.ref005]\], it has spread rapidly throughout the Middle East and subsequently in Europe, North Africa, North America, and Asia. Most OXA-48-producing isolates were *K*. *pneumoniae*; however, OXA-48 was also identified in other *Enterobacteriaceae*, such as *E*. *coli*, *Enterobacter* spp., *Klebsiella oxytoca*, *Citrobacter freundii*, and *Serratia marcecens* \[[@pone.0139152.ref013]\].

This is the first report of OXA-48-producing *K*. *pneumoniae* in Taiwan. All four isolates appeared in late 2013, but belonged to three different pulsotypes. Moreover, with the exception of cases 1 and 2, no epidemiologic linkage was identified between the 4 cases. The absence of *bla* ~OXA-48~ detection in the national surveillance program from 2012--2013 suggests that *bla* ~OXA-48~ is a new resistance gene; however, the epidemiologic data did not reveal that this carbapenemase gene was transmitted from other countries.

Previous studies reported that most *bla* ~OXA-48~ genes were located on a 62 kb self-conjugative plasmid in *Enterobacteriaceae* (pOXA-48a from the *K*. *pneumoniae* 11978 isolate from Turkey or plasmid pKP~OXA~-48N1) \[[@pone.0139152.ref012]\]. In 2013, a new 160-kb *bla* ~OXA-48~-encoding conjugative plasmid, pKP~OXA~-48N2, was characterized from *K*. *pneumoniae* \[[@pone.0139152.ref012]\]. The flanking region containing *bla* ~OXA-48~ in Taiwan isolates was identical to that observed in pKP~OXA~-48N1 \[[@pone.0139152.ref012]\]. Comparative analysis of the upstream region of three kinds of *bla* ~OXA-48~-carrying plasmids (pOXA-48a, pKP~OXA~-48N1, and our *bla* ~OXA-48~ plasmids) revealed that the plasmids have identical 164 bp sequences before the *bla* ~OXA-48~ start codon, including IS*1999* insertion sequences. Further upstream of this 164 bp sequence was a difference between pOXA-48a and pKP~OXA~-48N1. The sequence of our *bla* ~OXA-48~ carrying plasmids at approximately 950 bp upstream was identical to pKP~OXA~-48N1. Moreover, three plasmids exhibited very similar restriction profiles (*Eco*RI) over 60-kb, and matched the predicted digestion profile of pKP~OXA~-48N1. The plasmid digestion profile of that obtained from isolate 4 also had a similar restriction profile with the exception of containing one additional fragment of approximately 5-Kb. The results indicate the role of plasmids in the dissemination of *bla* ~OXA-48~. Approximately 80% of OXA-48 producers co-expressed ESBLs \[[@pone.0139152.ref014]\]; many OXA-48-producing isolates also carried CTX-M-15 \[[@pone.0139152.ref014]--[@pone.0139152.ref016]\]. In our OXA-48-producing isolates, three isolates also expressed CTX-M enzymes. According to previous surveillance data, the IncA/C-type plasmid was associated with *bla* ~CTX-M-15~(12.7%) in Asian countries \[[@pone.0139152.ref017]\]. In this study, three *bla* ~OXA-48-~containing plasmids also harboured *bla* ~CTX-M~ genes and belonged to the IncA/C group. Although most *bla* ~CTX-M-15~ were associated with the IncFIIA plasmid, the IncA/C plasmid has also been shown to be related with *bla* ~CTX-~M, and presumably the dissemination of CTX-M enzymes \[[@pone.0139152.ref017], [@pone.0139152.ref018]\]. Unlike the epidemic *bla* ~OXA-48~ plasmid incompatibility type, IncL/M \[[@pone.0139152.ref019]\], this is the second study to identify *bla* ~OXA-48~ on an IncA/C plasmid \[[@pone.0139152.ref020]\].

In an 11-year (2001--2011) molecular epidemiologic study of OXA-48 in Europe and North Africa, ST101 was the most frequently observed, followed by ST395 and ST15 in *K*. *pneumoniae*; ST11 was rarely detected \[[@pone.0139152.ref016]\]. In other regions, however, ST11 was the most prevalent ST type for multi-resistant *K*. *pneumoniae* \[[@pone.0139152.ref021]\]. OXA-48-producing isolates have been reported in Turkey, Argentina, and France \[[@pone.0139152.ref015],[@pone.0139152.ref022]\]. In Greece, an OXA-48-producing ST11 clone caused an outbreak \[[@pone.0139152.ref023]\]. With the exception of one isolate (ST116), three of the four OXA-48 producers identified in Taiwan belonged to ST11, the predominant sequence type outside Europe and North Africa. ST11 has been found in association with different ESBLs, primarily CTX-M-15, CTX-M-14, and SHV-5 \[[@pone.0139152.ref024], [@pone.0139152.ref025]\]. ST11 is also the predominant sequence type of imipenem non-susceptible *K*. *pneumoniae* isolates with resistance mechanisms other than OXA-48 in Taiwan \[[@pone.0139152.ref003]\]. Our report identified ST11 to be the major sequence type for OXA-48 producers.

In conclusion, we identified the first cluster of OXA-48 carbapenem-resistant *K*. *pneumoniae* in Taiwan. Although identification of OXA-48 producers is still sporadic in Asia, studies have predicted that OXA-group enzymes will successfully spread in the near future \[[@pone.0139152.ref026]\]. The association between OXA-48 and CTX-M could potentially lead to pan-β-lactam resistance \[[@pone.0139152.ref014]\]. Considering the high prevalence of ST11 *K*. *pneumoniae* and incorporation into the IncA/C plasmid with pandemic CTX-M enzymes, the emergence of OXA-48 is of great concern.
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